Refined structures of mouse P-glycoprotein

Jingzhi Li, Kimberly F. Jaimes, and Stephen G. Aller*

Department of Pharmacology and Toxicology, Center for Structural Biology, University of Alabama at Birmingham, Birmingham, Alabama, 35205

Received 30 August 2013; Revised 14 October 2013; Accepted 14 October 2013
DOI: 10.1002/pro.2387
Published online 24 October 2013 proteinscience.org

Abstract: The recently determined C. elegans P-glycoprotein (Pgp) structure revealed significant deviations compared to the original mouse Pgp structure, which suggested possible misinterpretations in the latter model. To address this concern, we generated an experimental electron density map from single-wavelength anomalous dispersion phasing of an original mouse Pgp dataset to 3.8 Å resolution. The map exhibited significantly more detail compared to the original MAD map and revealed several regions of the structure that required de novo model building. The improved drug-free structure was refined to 3.8 Å resolution with a 9.4 and 8.1% decrease in $R_{\text{work}}$ and $R_{\text{free}}$, respectively, ($R_{\text{work}} = 21.2\%$, $R_{\text{free}} = 26.6\%$) and a significant improvement in protein geometry. The improved mouse Pgp model contains $\sim 95\%$ of residues in the favorable Ramachandran region compared to only $57\%$ for the original model. The registry of six transmembrane helices was corrected, revealing amino acid residues involved in drug binding that were previously unrecognized. Registry shifts (rotations and translations) for three transmembrane (TM)4 and TM5 and the addition of three N-terminal residues were necessary, and were validated with new mercury labeling and anomalous Fourier density. The corrected position of TM4, which forms the frame of a portal for drug entry, had backbone atoms shifted $>6\text{ Å}$ from their original positions. The drug translocation pathway of mouse Pgp is 96% identical to human Pgp and is enriched in aromatic residues that likely play a collective role in allowing a high degree of polyspecific substrate recognition.

Keywords: P-glycoprotein; multidrug resistance; X-ray crystallography; SAD phasing; protein modeling

Introduction

P-glycoprotein (Pgp; ABCB1) may be the most promiscuous drug pump of any transporter in mammals, recognizing and effluxing possibly thousands of different small molecules from the cell. Understanding the molecular bases for polyspecific drug recognition by Pgp is critical for characterizing a major mechanism of multidrug resistance and for circumventing chemotherapeutic drug efflux. Achieving structural “snapshots” of drug-free and drug-bound conformations of Pgp would help shed light on the mechanisms of polyspecific drug recognition and folding of proteins in the ATP-Binding Cassette superfamily. Aller et al. reported the first
structure of Pgp that was captured in a conformation that is open to the cytoplasm including a distinct separation of nucleotide binding domains. This “inward-facing” conformation revealed portals open to the position of the lipid bilayer and a mechanism for extracting small molecules specifically from the inner (cytoplasmic) leaflet. Additional inward-facing structures with drugs bound to the internal cavity were presented, revealing amino acid residues involved in drug recognition including overlap with several residues previously identified by biochemical studies. The structure has been proposed to represent a nonphysiological conformation due to the absence of a lipid bilayer and nucleotide. Recent work by Wen et al. demonstrated that, in intact lipid bilayers in the presence or absence of nucleotide, Pgp is capable of opening wider—and closing down further—from the conformation in the original mouse Pgp crystal structure. Recent all-atom molecular dynamics (MD) simulations have also confirmed that inward-facing conformations of Pgp are highly plausible in the presence of an intact bilayer.

The original mouse Pgp structure was determined using multiwavelength anomalous dispersion (MAD) phasing with mercury labeled protein crystals. MAD phasing requires at least two datasets ($\lambda_1$ and $\lambda_2$) collected at different x-ray wavelengths for the same rotation sweep through the crystal. A single crystal was used (designated “Crystal2”), and the X-ray beam was positioned on the same location of the crystal for both datasets. In recent years, phasing by single-wavelength anomalous dispersion (SAD) has achieved greater prominence than MAD and now accounts for approximately half of the structures determined by experimental phasing methods. The increasing popularity of SAD phasing is largely due to the requirement of needing to collect only a single dataset from a single crystal, which minimizes radiation damage and diminishes nonisomorphism issues. The consequence of radiation damage was particularly noticeable for the Pgp $\lambda_2$ dataset, which exhibited reduced intensities and higher error ($R$-factor) for all resolution shells and very high error for the last two resolution shells (Supporting Information Table S1). The initial experimental electron density map for Crystal2 was produced incorporating data up to 4.5 Å (the maximum resolution for which a solution could be found). Modeling could not be performed de novo due to the limiting resolution of the experimental map, but relied on fitting regions of electron density with sections of the Sav1866 structure mutated to mouse Pgp residues. The original structure was then refined to the full 3.8 Å resolution to a final $R_{work}/R_{free}$ of 0.306/0.347. The final experimental electron density map was achieved by noncrystallographic symmetry (NCS) averaging of electron density contained within a mask of the two molecules in the asymmetric unit. Subsequently, two structures of mouse Pgp bound to stereoisomeric analogs of den-droamide-A, QZ-RRR, and QZ-SSS, were solved by molecular replacement, rigid body and simulated annealing refinement to 4.4 and 4.35 Å, respectively. The positions of the cyclic peptides were verified by visualization of the anomalous Fourier difference electron density arising from the selenium atoms in the cyclic peptides.

Jin et al. recently reported a higher resolution structure (3.4 Å) of PGP-1 from the nematode Caenorhabditis elegans. As with mouse Pgp, C. elegans PGP-1 was also captured in a drug-free inward-facing conformation but is even more open to the cytoplasm. Their detailed comparison of C. elegans PGP-1 to mouse Pgp revealed possible registry shifts of three transmembrane (TM) helices in the structure of the mouse ortholog. Furthermore, arginine-scanning mutagenesis by Loo et al. on human Pgp revealed discrepancies with the mouse Pgp structure at TM3 and TM5. To determine if the original mouse Pgp structural model could be improved, we produced a considerably higher quality experimental electron density map through SAD phasing of a single original mouse Pgp dataset ($\lambda_1$) to the full 3.8 Å resolution and model-independent density modification (DM). The quality of the map was sufficient to inspect all regions of the structure and to completely rebuild several TM regions de novo. Refinement of the improved structure was achieved with excellent statistics (9.4 and 8.1% decrease in $R_{work}$ and $R_{free}$, respectively, from previous values) revealing many significant differences compared to the original structure. The improved structure contains significant corrections to transmembrane helices (TM) 3–5, 8, 9, and 12 as well as corrections to three of four intracellular helices (also called coupling helices; IH1, IH3, and IH4), both “elbow helices,” both TMD-NBD connectors and minor corrections to all extracellular loops, each NBD and IH2. The improved drug-free structure was refined against the original QZ59-RRR and QZ59-SSS datasets to achieve a more accurate snapshot of drug binding. The improved structures reveal important implications for polyspecific drug recognition in the form of a high concentration of aromatic residues in the drug translocation pathway that is most conserved among mammalian orthologs.

Results

Scope of changes to Pgp model
To examine possible structural divergence between mouse- and C. elegans- Pgp, as well as ascertain whether any problems in modeling occurred in the original mouse Pgp structure, we calculated an experimental electron density map from single
anomalous dispersion (SAD) phasing of an original dataset \( (\lambda_1) \) that did not suffer from the effects of radiation damage during data collection nearly as much as the second dataset \( (\lambda_2) \). The experimental map was straightforward to produce using original mercury sites and NCS restraints (see Materials and methods section). The new SAD-phased map was superior in quality compared to the original MAD-phased map, revealing new details not previously visualized (Fig. 1). The appearance of more detail in the new map compared to original prompted a careful inspection of the entire structure. In all cases described below, corrections could be made using de novo modeling. The corrections to mouse Pgp structure are global, with 669 residues in the asymmetric unit (28%) have backbone C\(_a\) that are displaced more than 2 Å from their original positions (Fig. 2 and Supporting Information Fig. S1). Refinement of the structure resulted in a marked improvement in \( R_{\text{work}}/R_{\text{free}} \), Ramachandran favorability, bond angles and clash score, which were overlooked during quality control in the original model building (Table I).

Corrections to the mouse Pgp model, fully supported by new experimental electron density, were required as detailed in the accompanying supporting material (Supporting Information Figs. S2–S26). The most notable include: (1) a \( \sim 90^\circ \) rotation of the N-terminal elbow helix, (2) significant remodeling of intracellular helix 1, (3) a \( \sim 90^\circ \) rotation (one residue registry shift) of TM3, (4) A four-residue registry shift (\( \sim 360^\circ \) rotation and one-turn translation) for TM4, (5) remodeling extracellular loop 2, (6) a \( \sim 90^\circ \) rotation of TM5, (7) remodeling of the TM6-NBD connector (residues 368–385), (8) remodeling of the second elbow helix, (9) a one-residue registry correction for a portion of TM8 (residues 742–759), (10) a \( \sim 45^\circ \) rotation of a portion of TM9 (residues 828–849), (11) remodeling of IH4 as a proper helix, (12) remodeling of extracellular loop 6, (13) a rebuild of TM12 residues 968–987 to correct for a gradual and increasing registry error, and (14) a rebuild of TM12-NBD2 connector residues 1009–1028. Other corrections to TM1, TM2, TM6, TM7, TM10, and TM11 from refinement improved the positioning of dozens of side chains into new electron density that had poor or no substantial electron density representation in the original map. The totality of all changes made to the improved mouse Pgp structure resulted in a final \( R_{\text{work}}/R_{\text{free}} \) of 0.212/0.266 when refined against an original dataset. These \( R_{\text{work}}/R_{\text{free}} \) values represent a significant reduction (9.4%/8.1%) from the values describing the original published structure (16.6%/15.7% reductions for the last resolution shell).
Validation of TM registry shifts

The greatest changes to the mouse Pgp structure include registry shifts for the entire span of TM4 and TM5 (Fig. 2 and Supporting Information Fig. S1), each of which is relatively deficient in large side chains that would otherwise be straightforward to include registry shifts for the entire span of TM4 and TM5 (Fig. 2 and Supporting Information Fig. S1), each of which is relatively deficient in large side chains that would otherwise be straightforward to

Table I. Refinement and Model Statistics for Drug-Free Structures of P-Glycoprotein

|                          | Original mouse Pgp | Improved mouse Pgp | C. elegans PGP-1 |
|--------------------------|---------------------|--------------------|------------------|
|                          | PDB code 3G5U       | PDB code 4M1M      | PDB code 4F4C    |
| $R_{\text{work}}$ (CNS)  | 0.306 (0.448)$^{a}$ | 0.259$^{b}$ (0.353)$^{a}$ | 0.250 (0.342)$^{f}$ |
| $R_{\text{free}}$ (CNS)  | 0.347 (0.480)$^{a}$ | 0.303$^{b}$ (0.402)$^{a}$ | 0.283 (0.360)$^{f}$ |
| $R_{\text{work}}$ (Phenix)| 0.212 (0.282)$^{a}$ |                              |                  |
| $R_{\text{free}}$ (Phenix)| 0.266 (0.329)$^{a}$ |                              |                  |
| Clashscore, all atoms$^{d,e}$ | 124.1 (5$^{b}$)    | 10.22 (97$^{b}$)    | 7.55 (97$^{b}$)  |
| Poor rotamers$^{d}$       | 383 (20%)         | 43 (2.21%)         | 33 (3.35%)       |
| Ramachandran outliers$^{d}$ | 408 (17%)      | 14 (0.59%)         | 6 (0.48%)        |
| Ramachandran favored$^{d}$ | 1354 (57%)       | 2235 (95%)         | 1175 (94%)       |
| Molprobity score$^{d,f}$  | 4.47 (5$^{b}$)   | 2.15 (100$^{b}$)  | 2.19 (100$^{b}$) |
| $C_{\beta}$ deviations$^{d}$ | 6                | 2                 | 0                |
| Bad backbone bonds$^{d}$  | 1                 | 0                 | 0                |
| Bad backbone atoms$^{d}$  | 92                | 3                 | 1                |
| Rmsd bond lengths ($\AA$) | 0.010             | 0.005             | 0.009            |
| Rmsd bond angles ($^\circ$) | 1.900            | 0.970             | 1.200            |

$^{a}$ Highest resolution bin (4.04–3.80 $\AA$) is shown in parentheses.

$^{b}$ Model was refined with phenix.refine, but $R$ values were calculated with CNSv1.3 which ignores the anisotropy tensor terms.

$^{c}$ Highest resolution bin (3.61–3.40 $\AA$) is shown in parentheses.

$^{d}$ http://molprobity.biochem.duke.edu (using electron-cloud x-H bond-lengths and no N/Q/H flips).

$^{e}$ Percentile score at the time of this publication is shown in parentheses.

$^{f}$ MolProbity score combines the clashscore, rotamer, and Ramachandran evaluations into a single value.
visualize in mid-resolution maps, if ordered. Registry corrections in α-helices have significant impact on side chains because, even if the $C_a$ distance shift for a residue is modest, the changes to the side chain atoms are amplified since they point in a very different direction and shift greater distances. Three additional residues were also added to the N-terminus that were not previously modeled. To validate the changes to TM4, TM5, and the N-terminus, we have replaced selected residues in these regions with cysteine and labeled with mercury to pinpoint their locations. Anomalous difference electron density revealed mercurated cysteines at locations that strongly support the improved structure (Fig. 3). Our results confirm a full registry shift was required for TM4 and a partial shift for TM5, each involved in a crossover motif that communicates information between TM domains and nucleotide binding. TM4 may also play an important role in selecting drugs from the lipid bilayer, since it forms one of the portals open to the inner leaflet.

The drug translocation pathway of P-glycoprotein

The improved mouse Pgp structure agrees well with several reports that examine the location of drug-binding residues as well as crosslinking between TM2 and TM11, TM5 and TM8, NBD1 and IH4, and NBD2 and IH2 (Fig. 4). The improved drug-free structure allowed straightforward structure refinement against original datasets of mouse Pgp crystals grown in the presence of the cyclic peptides (QZ59-RRR and QZ59-SSS). Refinement resulted in $R_{\text{work}}/R_{\text{free}}$ values that were 9.1/7.6 and 8.2/7.7%, respectively, lower than the previously published values (Supporting Information Table S2).

We summarize the drug-binding cavity for QZ59-RRR and QZ59-SSS, including residues that extend to the ceiling of the cavity and more residues previously shown to interact with verapamil (Fig. 5). The pathway contains nine aromatic residues that are identical in human and mouse Pgp but are not conserved in C. elegans PGP-1 (Supporting Information Fig. S27).

Overall, the conservation of 46 residues in the drug translocation pathway between mouse and C. elegans PGP-1 is rather low at 13% sequence identity, whereas human- and mouse-Pgp are 96% identical (Supporting Information Table S3). Mammalian orthologs of Pgp also contain no charged residues penetrating into the translocation pathway, which is in contrast to the bacterial lipid flippases (such as MsbA) as well as C. elegans PGP-1 (Supporting Information Fig. S28). MsbA, which has 16 formally charged residues pointed directly toward the substrate translocation pathway, is a well-characterized lipid-A flippase. The presentation of charged residues by lipid flippases to the hydrophobic section

![Figure 3. Validation of N-terminus and TM Registry Shifts. Using a Cysless mouse Pgp as template, three additional mutants were constructed, crystallized, and labeled with mercury.](image-url)
of the bilayer is reminiscent of α-helical proteins and amphipathic α-helical peptides that exhibit reversible lipid binding in a membrane.\textsuperscript{30,31} Taken together, the composition of the 46 residues of the translocation pathway in Pgp provides structural evidence that a significant amount of drug–protein interaction is likely to be electrostatic,\textsuperscript{32} including a strong component of cation–π, CH–π, or π–π recognition.\textsuperscript{33,34} The aromatic residues in the mouse Pgp drug translocation pathway could provide strong affinity for substrates with lower geometric constraints compared to hydrogen bonding, and a consequently lower entropic penalty of binding drug substrates.

Conserved folding motifs in ABC proteins

In the maltose importer MalK, transmembrane extensions in the form of intracellular helices (IHs) make critical contacts with the nucleotide binding domains (NBDs) that are maintained by salt bridges during conformational cycling.\textsuperscript{35,36} Salt bridging between NBDs-IHs is a widely conserved feature in both bacterial and mammalian ATP-Binding Cassette (ABC) proteins, and in both importers and exporters.\textsuperscript{36} A salt bridge (Asp-Arg), engaged in polar contact with a tyrosine forming an interacting triad, appears twice (related by twofold pseudosymmetry) in the high-resolution crystal structure of \textit{C. elegans} PGP-1. One triad forms a basis of the IH1-IH4-NBD1 interface and the second triad forms the IH2-IH3-NBD2 interface.\textsuperscript{14} Our new experimental electron density map showed good contiguous electron density for the corresponding interfaces of mouse Pgp (Supporting Information Fig. S29, A,G), allowing correct modeling of the salt bridging triad in the improved structure [Fig. 6(A–D)]. The interfaces are incorrectly modeled in all recent structures of mouse Pgp\textsuperscript{37} including an attempt to correct the original structure without an accompanying manuscript or supporting data (PDB code 4LSG; Supporting Information Fig. S29, C–F, I–L).

An additional salt bridge just above IH2 (E256-R276) connecting intracellular extensions of TM4 and TM5 was shown to be critical for bioprocessing and folding of human Pgp in recent biochemical experiments.\textsuperscript{38} Charge reversal at either site (individually) blocked mature glycosylation, but the double charge reversal mutant (E256R/R276E) allowed protein maturation and restored verapamil-stimulated ATPase activity to wildtype levels. This region had substantial modeling errors in the original structure [Fig. 6(E)]. Close inspection of the new
Interfacial residues between NBD1 and ICL4 (IH4) share some conservation among all mammalian ABC proteins, including the only channel protein in the superfamily, CFTR/ABCCT. The NBD1-ICL4 interface contains an aromatic residue (either Tyr or Phe) that is invariant in all five mammalian ABC subfamilies (A, B, C, D, and G). A deletion of Tyr or Phe) that is invariant in all mammalian ABC proteins, including the only channel protein in the superfamily, CFTR/ABCCT. The NBD1-ICL4 interface contains an aromatic residue (either Tyr or Phe) that is invariant in all five mammalian ABC subfamilies (A, B, C, D, and G). A deletion of Tyr or Phe) that is invariant in all mammalian ABC subfamilies (A, B, C, D, and G). A deletion of the interfacial aromatic residue in CFTR (Phe 508) appears that deficient interaction energy at the interface as a result of the F508del mutation of CFTR can be partly compensated for by augmenting interaction energy nearby. Our improved structure shows that mouse Pgp Arg 908 is in very close proximity to position 488 (Fig. 7), which is the comparable position to CFTR Val 510, and confirms that these two positions are sufficiently close for engineering a salt bridge. Close inspection of the interface in our improved structure suggests that a prefolded state of Pgp, and by inference CFTR, would seem to include cation–π interactions between Arg 908 or Lys 911 and Tyr 486 as NBD1 and ICL4 approach each other during folding. When contact between NBD1 and ICL4 is achieved as visualized in the folded, correct structure, Arg 908 and Lys 911 turn to the side and interact with other residues as they avoid steric clash with NBD1. If this folding dynamic is confirmed, then small molecules that mimic similar bridging between NBD1 and ICL4 may be effective at assisting the folding the major CF mutation, CFTR-F508del.

Discussion

The recent 3.4 Å structure of C. elegans PGP-1 and careful comparisons of Jin et al.\textsuperscript{14} to the original mouse Pgp structure revealed problems in mouse Pgp model in TMs 3, 4, and 5. The discovery prompted a thorough inspection and complete rebuild of the mouse Pgp structure that required global corrections to the model. The corrections to the mouse Pgp structure presented here were only possible after producing an improved experimental electron density map. What criteria allow us to conclude that our new map is improved? The “phasing power” statistic is useful for older algorithms that employ least squares minimization such as PHASES (Furey, 1997) that was used in the original MAD phasing solution of mouse Pgp. The phasing power reported for the 3.8 Å mouse Pgp MAD solution was rather low at 1.32 compared to the author’s original 4.5 Å map from “Crystal 1” that had a phasing power of 3.1 (Aller et al., Science 2009, Supporting Information Table S1). Phasing power, however, is not useful for the more recent maximum likelihood based routines such as PHASER\textsuperscript{41} used in this work. Another statistic, figure of merit (FOM), must
be used with care because values are not directly comparable for MAD- versus SAD-phasing solutions. In general, for a MAD dataset, a FOM of 0.5 is acceptable, 0.6 is good, and anything above 0.7 is very good. For a SAD dataset, a FOM of 0.3 is acceptable, 0.4 is good, and anything above 0.5 is very good. The original mean FOM for the original 3.8 Å MAD solution was reported to be 0.434 (Aller et al, Science 2009, Supporting Information Table S1), which falls short of what is generally considered

Figure 6. Interdomain polar contacts in the improved mouse P-glycoprotein structure. (A and B) View of IH1-IH4-NBD1 polar contacts in molecules “A” and “B” of the asymmetric unit, respectively. (C and D) View of IH2-IH3-NBD2 polar contacts in molecule “A” and “B,” respectively. (E) Incorrect modeling of the TM4-TM5 region connecting IH2 in the original mouse Pgp structure. The Glu 252–Arg 272 pair, just above IH1, was modeled more than 11 Å apart in the original structure. (F) A salt bridge between Glu 252 and Arg 272, required for proper folding of Pgp, is shown for one molecule of the asymmetric unit in the improved structure.
to be acceptable. This may likely explain the lack of detail in the original experimental map. The mean FOM of our SAD phasing solution is 0.336 prior to any DM, and is in the acceptable range.

More appropriate phasing statistics have recently been described. Terwilliger et al. performed a comprehensive analysis for assessing the quality of experimental maps using 246 structures recently determined by the Joint Center for Structural Genomics (JCSG). These authors showed that the single best measure for evaluating the quality of experimental maps prior to density modification (DM) is the Bayesian estimator based on skewness (skew) of the density values. The correlation between estimated and actual map quality for this single statistic was an impressive 90%. The combination of two measures, skew and the correlation of local rms density ($r^2_{\text{RMS}}$), gave a further improvement in estimating map quality with an overall correlation coefficient of 92%. The new SAD experimental map had a skew value of 0.11, which is expected to be positive for good experimental maps that should lack negative electron density. Furthermore, our SAD map yielded a $r^2_{\text{RMS}} = 0.85$, which scores in the top 72nd percentile (986/1359) among the 1359 JCSG maps (includes all solutions for all structures). The correlation of local rms density ($r^2_{\text{RMS}}$) for our phasing solution may be even more significant considering that all of the JCSG datasets were of much higher resolution (a 2.5 Å cutoff was used to produce all JCSG maps).

To produce an improved unbiased experimental electron density map, DM is typically performed using one of several model-independent methods to determine protein-solvent boundaries. The Wang method of DM was clearly preferred in the construction of the new SAD map resulting in a final overall $R_{\text{factor}} = 0.238$ compared to either the histograms method ($R_{\text{factor}} = 0.307$) or classic method ($R_{\text{factor}} = 0.603$). This is consistent with the observed advantage of the Wang method in reducing the influence on the overall DM process of strong anomalous scatterers such as the mercury labeling we employed for phasing. In assessing quality of experimental maps however, there is no substitute for close visual inspection of electron density. Our unbiased experimental SAD map following DM using the Wang method and implementing NCS found in the original published structure revealed side chain details of the protein not previously visualized (Fig. 1). Real space cross-correlation analysis (Supporting Information Table S4) confirmed that our improved Pgp model had the highest overall correlation to the new SAD experimental map compared to the original MAD map. Furthermore, the improved structure had a significantly higher number of residues covered by acceptable electron density.

Considering the extent of validation offered in the Supporting Information accompanying the original mouse Pgp publication, how did errors carry over into the original structure? The authors...
presented multiple composite Fo-Fc maps as well as a Sigma-A weighted 2Fo-Fc composite simulated annealing omit map to validate their structure, because details were absent in the original experimental map. Caution should be taken with such a strategy because all difference maps rely on model phases, which can introduce model bias. Specifically, errors likely carried over into the difference maps because once the original atomic model was refined, the positions and other parameters describing the majority of correctly placed atoms were subjected to minor adjustments during refinement to compensate for the minority of incorrectly placed atoms. Consequently, even when the incorrectly placed atoms were removed from the model before the calculation of phases (when using omit maps), a memory of their positions remained and the resulting difference maps retained incorrect features. To avoid such errors in the future, we consider it critical to achieve a high-quality experimental electron density map yielding good phasing statistics and exhibiting features that are consistent with the claims of the resolution of the refined structure. Relatedly, Ward et al. recently published new structures of mouse Pgp in the absence or presence of a camel antibody. A low-resolution (4.5 Å) experimental map was produced revealing a conformation even more open to the cytoplasm. The structures do appear to contain registry corrections to TMs 3–5, likely prompted by the more recent C. elegans PGP-1 structure, but other discrepancies still persist in regions not validated by their cysteine labeling, most notably: (1) intracellular helix 1 (IH1) is ~90° out of register; (2) polar contacts at NBD-II interfaces are incorrectly modeled; (3) a segment of TM8 (residues 742–759) remains ~90° out of register; (4) a portion of TM9 (residues 828–849) remains ~45° out of register; (5) a gradual and increasing registry error remains for TM12 residues 968–987 as shown by our new anomalous data (see Supporting Information Fig. S30), and 6 the registry error of the N-terminal elbow/6 the registry error of the N-terminal elbow helix (EH1) by ~90° prevented correct modeling of the salt bridge between Arg40-Asp366 (EH1 and TM6). This pair clearly forms a bridge in mouse Pgp as revealed by new experimental density (Supporting Information Fig. S2, C). Curiously, the corresponding conserved pair in C. elegans PGP-1, Arg67, and Asp394, are too far away to form a salt bridge, whereas the pseudosymmetry related pair connecting EH2 and TM12 in both PGP-1 (Glu742-Arg1056) and mouse Pgp (Arg695-Glu1009) are sufficiently close in the structures to form salt bridges. We note that the all of the above modeling errors are also present in a recent attempt to correct the original mouse Pgp structure with a released PDB entry (4LSG), which has $R_{work}/R_{free}$ values that are actually worse than the original values. It would appear, therefore, that modeling errors have propagated in all mouse Pgp structures to date originating from errors in the original structure due to insufficient detail in the experimental map. This problem is reminiscent of the retractions surrounding MsbA structures, in which swapping columns of anomalous data does not explain the root cause of the continuing propagation of errors in the various structures.

The 3.4 Å structure of C. elegans PGP-1 revealed an inward-facing conformation that is even more open to the cytoplasm (the nucleotide binding domains are separated by an additional 16 Å) compared to mouse Pgp. Thus, a high degree of flexibility is evolutionarily conserved in Pgp allowing the transporter to open to the inner leaflet for extracting small molecules from the membrane. It is noteworthy that rather hydrophilic substrates might be capable of gaining access to the drug translocation pathway directly from the cytoplasm. The 16 Å spacing difference between original mouse Pgp and C. elegans PGP-1 structures makes particular regions difficult to compare. Likewise, the C. elegans genome contains at least 20 orthologs and isoforms of ABCB-like proteins, compared to two ABCB1 orthologs in mouse (ABCB1A and ABCB1B), and only one in human. C. elegans PGP-1 has 46% identity to human Pgp and 43% identity to mouse Pgp (ABCB1A), whereas human ABCB1 and mouse ABCB1A are 87% identical. The lack of charged residues in the drug-translocation pathway of mammalian Pgp compared to nematode Pgp or bacterial lipid flippases suggests evolution of differing functions. The charged residues of a lipid flippase could serve to lower the relatively large energy barrier of pulling phospholipid headgroups, which bear formal charge, into the translocation pathway. Mammalian Pgp seems to prefer aromatic residues in the drug translocation pathway possibly to maximize polyspecific recognition and export of neutral/cationic small molecules that are rich in sp2 hybridization. Relatedly, Jin et al. demonstrated that, of the many drug compounds that are known to stimulate human Pgp, only a small subset could stimulate the ATPase activity of C. elegans PGP-1 which contains fewer aromatic residues in the drug translocation pathway compared to human Pgp. Thus, it could be that C. elegans achieves polyspecificity by employing a greater number of genomic orthologs of Pgp that each are relatively more specific for certain substrates compared to the single ortholog in humans.

Phylogenetic analysis reveals a large jump in divergence of nematode Pgp compared to their vertebrate counterparts (Supporting Information Fig. S31). We therefore produced a homology model of human Pgp based on the improved mouse structure as the more appropriate template in order to minimize errors arising from evolutionary divergence. Our human Pgp model exhibits good protein
was conducted to the full 3.8 Å resolution of the set to 8.0 (no new sites were found). SAD phasing Z-score cutoff for accepting peaks as new atoms was manually inspected the goodness of fit in experimen-

was added prior to a final round of refinement. We from a near-final refined improved model and

conversion to CCP4-style maps for figure rendering coefficients were explicitly written out to facilitate

mercury sites with phenix.phaser.41,46 The minimum distance between sites was fixed at 3 Å and a

difference Fourier density. The docked structures were
docked into the structures (in both possible orienta-
tions), placing the selenium atoms in anomalous dif-
frames (Supporting Information Table S6), placing the selenium atoms in anomalous Fourier maps, and the vicinity of the drug was carefully inspected. As was originally discovered, the “upper” QZ59-SSS mole-
cule was significantly disordered since Fo-Fc density was absent for two vertices of the triangular drug molecule. These atoms were subsequently removed from the final version of the structure.

Materials and Methods

SAD phasing, structure rebuilding, and refinement

The new experimental electron density map was produced using an original dataset (“Dataset #1”, Supporting Information Table S1) and 12 original mercury sites with phenix.phaser.41,46 The minimum distance between sites was fixed at 3 Å and a Z-score cutoff for accepting peaks as new atoms was set to 8.0 (no new sites were found). SAD phasing was conducted to the full 3.8 Å resolution of the dataset. Model-free phases were subjected to Wang-based DM42 and twofold NCS restraints (Supporting Information Table S6) using RESOLVE47 within PHENIX.46 NCS operators were determined from the original mouse Pgp structure (3G5U) using the phenix.python script simple_ncs_from_pdb.py. A temperature factor of ~38 Å² was applied to sharpen the electron density map (see Supporting Information Table S4). Hendrickson–Lattman map coefficients were explicitly written out to facilitate conversion to CCP4-style maps for figure rendering within PyMol.48

An anomalous difference Fourier map produced from a near-final refined improved model and “Dataset #1” revealed a 13th mercury site, which was added prior to a final round of refinement. We manually inspected the goodness of fit in experimen-
tal electron density for all residues of each molecule in the asymmetric unit. Most of the corrections could be made by manually dragging the peptide chain into density or using “Real Space Refine Zone” or “Auto Fit Rotamer” options within Coot.49 For each of TM3, 4, and 5, the entire helix was deleted and rebuilt as regularized helical sections using the “Place Helix Here” function within Coot, and then manually editing of the positions of main chain and side chain atoms to fit within density. Since “Dataset #1” (α = 97.72, β = 115.68, and γ = 378.98) is virtually isomorphous with the original published unit cell dimensions (α = 97.54, β = 115.43, and γ = 378.86), we chose to refine against the original published structure factors which preserved all original reflections flagged for the test set. Refinement was performed with phenix.refine against the maximum likelihood target using NCS restraints and secondary structure restraints, group B-factor, individual B-factor, and restraining NCS-related B-factors. Refinement was always performed using TLS,50 as defined by the following: chain “A” (eight groups): residues 30–99, 100–366, 367–592, 593–736, 737–884, 885–960, 961–1079, and 1080–1271; and chain “B” (seven TLS groups): residues 31–208, 209–317, 318–592, 593–736, 737–967, 968–1044, and 1045–1271.

Refinement of cyclic peptide bound structures
To achieve improved structures of cyclic peptides bound to mouse Pgp, the final drug-free mouse Pgp structure was first refined into the 4.4 Å QZ59-RRR and 4.35 Å QZ59-SSS datasets without drug (rigid body, TLS, NCS, group-, and individual- B-factors). Anomalous difference Fourier maps were then calculated (CNSv1.3) from model phases of the refined structures to pinpoint the location of the selenium atoms in the datasets. Regularized molecules of the RRR- and SSS-cyclic peptides were then manually docked into the structures (in both possible orientations), placing the selenium atoms in anomalous difference Fourier density. The docked structures were then subjected to another round of refinement using cyclic peptide parameter files with the exception that rigid body refinement was omitted. To examine the orientation of the drugs, refined structures were used to calculate Fo-Fc difference maps, and the vicinity of the drug was carefully inspected. As was originally discovered, the “upper” QZ59-SSS mole-
cule was significantly disordered since Fo-Fc density was absent for two vertices of the triangular drug molecule. These atoms were subsequently removed from the final version of the structure.

Cysteine labeling and anomalous Fourier
Cysteine mutants were introduced on a cysteless mouse Pgp construct and subjected to refinement
against their respective datasets (Supporting Information Table S7) as described.1

**Figures**

Figures were generated using PyMol48 and Adobe Photoshop 7.0. Figure 2 was created using the python script “rmsd_b.py” downloaded from the PyMol script repository hosted by the Molecular Modeling and Crystallographic Computing Facility at Queen’s University. This script calculated the pairwise rmsd for each backbone atom in the original Pgp structure (3G5U) and the improved structure (4M1M), and replaced the b-factor array with the rmsd values. The figure was colored by rmsd using the standard b-factor coloring mode within PyMol.

**Coordinates**

The improved drug-free and cyclic-peptide bound structures of mouse Pgp have been deposited to the Protein Data Bank with accession codes 4M1M, 4M2S, and 4M2T.

**Acknowledgments**

The authors declare no competing financial interests or conflicts of interest. The authors thank Dr Thomas Terwilliger for suggesting the cross-correlation analysis.

**References**

1. Aller SG, Yu J, Ward A, Weng Y, Chittaboina S, Zhuo R, Harrell PM, Trinh YT, Zhang Q, Urbatsch IL, Chang G (2009) Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 323:1718–1722.
2. Chen Y, Pant AC, Simon SM (2001) P-glycoprotein does not reduce substrate concentration from the extracellular leaflet of the plasma membrane in living cells. Cancer Res 61:7763–7769.
3. Shapiro AB, Ling V (1998) Transport of LDS-751 from the cytoplasmic leaflet of the plasma membrane by the rhodamine-123-selective site of P-glycoprotein. Eur J Biochem 254:181–188.
4. Shapiro AB, Ling V (1997) Extraction of Hoechst 33342 from the cytoplasmic leaflet of the plasma membrane by P-glycoprotein. Eur J Biochem 250:122–129.
5. Romsicki Y, Sharom FJ (2001) Phospholipid flipase activity of the reconstituted P-glycoprotein multidrug transporter. Biochemistry 40:6957–6947.
6. Loo TW, Bartlett MC, Clarke DM (2010) Human P-glycoprotein is active when the two halves are clamped together in the closed configuration. Biochem Biophys Res Commun 395:436–440.
7. Gottesman MM, Ambudkar SV, Xia D (2009) Structure of a multidrug transporter. Nat Biotechnol 27:546–547.
8. Wen PC, Verhalen B, Wilkens S, McHaourab H, Tajkhorshid E (2013) On the origin of large flexibility of P-glycoprotein in the inward-facing state. J Biol Chem 288:19211–19220.
9. Wise JG (2012) Catalytic transitions in the human MDR1 P-glycoprotein drug binding sites. Biochemistry 51:5125–5141.
10. Dauter Z, Dauter M, Dodson E (2002) Jolly SAD. Acta Cryst D 58:494–506.
11. Read RD, McCoy AJ (2011) Using SAD data in Phaser. Acta Cryst D 67:338–344.
12. Dawson RJP, Locher KP (2006) Structure of a bacterial multidrug ABC transporter. Nature 443:180–185.
13. Ogino J, Moore RE, Patterson GM, Smith CD (1996) Dendroamides, new cyclic hexapeptides from a blue-green alga. Multidrug-resistance reversing activity of dendroamide A. J Nat Prod 59:581–586.
14. Jin MS, Oldham ML, Zhang Q, Chen J (2012) Crystal structure of the multidrug transporter P-glycoprotein from Caenorhabditis elegans. Nature 490:566–569.
15. Loo TW, Bartlett MC, Clarke DM (2009) Identification of residues in the drug translocation pathway of the human multidrug resistance P-glycoprotein by arginine mutagenesis. J Biol Chem 284:24074–24087.
16. Loo TW, Bartlett MC, Clarke DM (2006) Transmembrane segment 1 of human P-glycoprotein contributes to the drug-binding pocket. Biochem J 396:537–545.
17. Loo TW, Bartlett MC, Clarke DM (2006) Transmembrane segment 7 of human P-glycoprotein forms part of the drug-binding pocket. Biochem J 399:351–359.
18. Loo TW, Bartlett MC, Clarke DM (2007) Suppressor mutations in the transmembrane segments of P-glycoprotein promote maturation of processing mutants and disrupt a subset of drug-binding sites. J Biol Chem 282:32043–32052.
19. Loo TW, Clarke DM (2005) Do drug substrates enter the common drug-binding pocket of P-glycoprotein through “gates”? Biochem Biophys Res Commun 329:419–422.
20. Loo TW, Clarke DM (2013) Drug rescue distinguishes between different structural models of human P-glycoprotein. Biochemistry 52:7167–7169.
21. Loo TW, Bartlett MC, Clarke DM (2004) Val133 and Cys137 in transmembrane segment 2 are close to Arg935 and Gly939 in transmembrane segment 11 of human P-glycoprotein. J Biol Chem 279:18232–18238.
22. Loo TW, Bartlett MC, Clarke DM (2004) Disulfide cross-linking analysis shows that transmembrane segments 5 and 8 of human P-glycoprotein are close together on the cytoplasmic side of the membrane. J Biol Chem 279:7692–7697.
23. Zolnerciks JK, Woolding C, Linton KJ (2007) Evidence for a Sav1866-like architecture for the human multidrug transporter P-glycoprotein. FASEB J 21:3937–3948.
24. Loo TW, Bartlett MC, Clarke DM (2008) Processing mutations disrupt interactions between the nucleotide binding and transmembrane domains of P-glycoprotein and the cystic fibrosis transmembrane conductance regulator (CFTR). J Biol Chem 283:28190–28197.
25. Ward A, Reyes CL, Yu J, Roth CB, Chang G (2007) Flexibility in the ABC transporter MabA: alternating access with a twist. Proc Natl Acad Sci USA 104:19005–19010.
26. Borbat PP, Surendhran K, Bortolus M, Zou P, Freed JH, McHaourab HS (2007) Conformational motion of the ABC transporter MabA induced by ATP hydrolysis. PLoS Biol 5:e271.
27. van Veen HW, Callaghan R, Soceneantu L, Sardini A, Konings WN, Higgins CF (1998) A bacterial antibiotic-resistance gene that complements the human multidrug-resistance P-glycoprotein gene. Nature 391:291–295.
28. Doerrler WT, Reedy MC, Raetz CR (2001) An Escherichia coli mutant defective in lipid export. J Biol Chem 276:11461–11464.
29. Zhou Z, White KA, Polissi A, Georgopoulos C, Raetz CR (1998) Function of Escherichia coli MsbA, an essential ABC family transporter, in lipid A and phospholipid biosynthesis. J Biol Chem 273:12466–12475.

30. Segrest JP, Jones MK, Mishra VK, Anantharamaiah GM (2002) Experimental and computational studies of the interactions of amphipathic peptides with lipid surfaces. Curr Top Membr 52:397–435.

31. Borhani DW, Rogers DP, Engler JA, Brouillette CG (1997) Crystal structure of truncated human apolipoprotein A-I suggests a lipid-bound conformation. Proc Natl Acad Sci USA 94:12291–12296.

32. Li-Blatter X, Seelig A (2010) Exploring the P-glycoprotein binding cavity with polyoxyethylene alkyl ethers. Biophys J 99:3589–3598.

33. Plevin MJ, Bryce DL, Boisbouvier J (2010) Direct detection of CH/pi interactions in proteins. Nat Chem 2:466–471.

34. Toth G, Bowers SG, Truong AP, Probst G (2007) The role and significance of unconventional hydrogen bonds in small molecule recognition by biological receptors of pharmaceutical relevance. Curr Pharm Des 13:3476–3493.

35. Khare D, Oldham ML, Orelle C, Davidson AL, Chen J (2009) Alternating access in maltose transporter mediated by rigid-body rotations. Mol Cell 33:528–536.

36. Mourez M, Hofnung M, Dassa E (1997) Subunit interactions in ABC transporters: a conserved sequence in hydrophobic membrane proteins of periplasmic permeases defines an important site of interaction with the ATPase subunits. EMBO J 16:3066–3077.

37. Ward AB, Szewczyk P, Grimard V, Lee CW, Martinez L, Doshi R, Caya A, Villaluz M, Pardon E, Cregger C, Swartz DJ, Falson PG, Urbatsch IL, Govaerts C, Steyaert J, Chang G (2013) Structures of P-glycoprotein reveal its conformational flexibility and an epitope on the nucleotide-binding domain. Proc Natl Acad Sci USA 110:13386–13391.

38. Loo TW, Clarke DM (2013) A salt bridge in intracellular loop 2 is essential for folding of human P-glycoprotein. Biochemistry 52:3194–3196.

39. Loo TW, Bartlett MC, Clarke DM (2002) Introduction of the most common cystic fibrosis mutation (Delta F508) into human P-glycoprotein disrupts packing of the transmembrane segments. J Biol Chem 277:27585–27588.

40. Loo TW, Bartlett MC, Clarke DM (2010) The V510D suppressor mutation stabilizes DeltaF508-CFTR at the cell surface. Biochemistry 49:6352–6357.

41. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ (2007) Phaser crystallographic software. J Appl Cryst 40:658–674.

42. Wang BC (1985) Resolution of phase ambiguity in macromolecular crystallography. Methods Enzymol 115:90–112.

43. Chang G (2007) Retraction of “Structure of MsbA from Vibrio cholera: a multidrug resistance ABC transporter homolog in a closed conformation” [J Mol Biol (2003) 330 419–430]. J Mol Biol 369:596.

44. Chang G, Roth CB, Reyes CL, Pornillos O, Chen YJ, Chen AP (2006) Retraction. Science 314:1875.

45. Matthews BW (2007) Five retracted structure reports: inverted or incorrect? Protein Sci 16:1013–1016.

46. Adams PD, Afonine PV, Bunkoczi G, Chen VB, Davis IW, Echols N, Headd JJ, Hung LW, Kapral GJ, Groske-Kunstleve RW, McCoy AJ, Moriarty NW, Oeffner R, Read RJ, Richardson DC, Richardson JS, Terwilliger TC, Zwart PH (2010) PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Cryst D 66:213–221.

47. Terwilliger TC (2003) SOLVE and RESOLVE: automated structure solution and density modification. Methods Enzymol 374:22–43.

48. DeLano WL (2002) The PyMol Molecular Graphics System, Version 1.5.0.4 Schrodinger, LLC.

49. Emsley P, Cowtan K (2004) Coot: model-building tools for molecular graphics. Acta Cryst D 60:2126–2132.

50. Painter J, Merritt EA (2006) Optimal description of a protein structure in terms of multiple groups undergoing TLS motion. Acta Cryst D 62:439–450.

51. Loo TW, Clarke DM (2001) Defining the drug-binding site in the human multidrug resistance P-glycoprotein using a methanethiosulfonate analog of verapamil, MTS-verapamil. J Biol Chem 276:14972–14979.

52. Loo TW, Clarke DM (1997) Identification of residues in the drug-binding site of human P-glycoprotein using a thiol-reactive substrate. J Biol Chem 272:31945–31948.

53. Loo TW, Bartlett MC, Clarke DM (2003) Methanethiosulfonate derivatives of rhodamine and verapamil activate human P-glycoprotein at different sites. J Biol Chem 278:50136–50141.